UK

Boltz Raises $110Mn in Series A Funding to Advance AI-Powered Drug Discovery

Nov 19, 2026 | By Oliver Bennett

Boltz Raises $110Mn in Series A Funding to Advance AI-Powered Drug Discovery

London-based AI drug discovery startup Boltz has raised $110 million in a Series A funding round, less than a year after coming out of stealth mode.

The company develops AI models that help researchers speed up the drug discovery process. Boltz originally started at the Massachusetts Institute of Technology (MIT) in the US and is now based in London. It has a team of 40 AI researchers working from its office in the King's Cross area.

The funding round was led by Bessemer Venture Partners. Existing investors, including Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures, also took part in the round.

Boltz said: ‘We believe we are still just at the beginning of an exponential trajectory in model capabilities. Our upcoming models are already showing substantial improvements in the quality of the molecules they generate. Our long-term goal remains a world where a scientist can go from a therapeutic hypothesis to a human-ready molecule without leaving their computer. Reaching that goal will require further advances in the models and substantial investment in compute and data.”

Boltz's AI models can predict how proteins and potential drug molecules interact with each other. They can also estimate how strongly these molecules bind together and suggest new molecules that could work against specific targets.

The company develops open-source AI models and also offers other models through its own platform and API. This allows researchers and drug developers to use its technology for their work.

Boltz banner with the logo, headline “AI that designs the molecules of tomorrow,” a molecule drawing, and stats like 5M+ downloads and 100k+ scientists.

During its time at MIT, Boltz's co-founders released open-source AI models that performed as well as some closed-source models, including DeepMind's AlphaFold3. These models are now being used as standard tools in early-stage drug discovery.

Boltz has also announced partnerships with major pharmaceutical companies, including Pfizer, GSK, Takeda and Bristol Myers Squibb.

The company makes money through partnerships and by giving businesses and researchers access to its AI platform and models.

Read Also- Stockholm-Based Wilgot Secures $3Mn to Boost Brand Visibility in AI Assistants

Recommended Stories for You